Vancomycin
Immune Checkpoint Inhibitor
Sun Yat-sen UniversitySmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Immune Checkpoint Inhibitor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tislelizumab Guangxi Medical University | Phase 3 | B |
Theprubicin Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | B |
Toripalimab Sun Yat-sen University | Phase 2 | B |
LENVATINIB Guangxi Medical University | Phase 3 | B |
Ethiodized Oil Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | B |
View all 22 →
Same molecule, other indications
Vancomycin is also rated in:
methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
68 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →